AIDS

AIDS is a major clinical context for understanding kidney disease in patients who are also infected with hepatitis C virus. In this evidence, it is not treated as a single renal diagnosis: HIV-associated nephropathy, immune-complex glomerulonephritis, metabolic kidney injury, and hepatitis C virus–related cryoglobulinemic membranoproliferative glomerulonephritis may coexist or be difficult to distinguish. The resulting condition is shaped not only by viral pathology but also by antiretroviral treatment, dialysis, transplantation, diagnostic classification, and long-term quality of life.

Renal Disease in AIDS

AIDS-associated kidney disease includes HIV-associated nephropathy, a collapsing form of focal glomerulosclerosis regarded as the most representative glomerular disease in HIV-infected patients. It typically presents with nephrotic syndrome and, without treatment, rapidly worsening renal function. Renal biopsy shows collapsing focal glomerulosclerosis, marked podocyte hypertrophy, and tubulointerstitial changes; immunofluorescence may show isolated IgM and C3, while electron microscopy does not show immune-complex deposits.

The renal picture in patients with AIDS is broader than HIV-associated nephropathy. HIV-infected patients may develop immune-complex glomerulonephritis, including membranoproliferative glomerulonephritis, IgA nephropathy, non-collapsing focal segmental glomerulosclerosis, membranous nephropathy, and lupus-like glomerulonephritis. Hypertensive nephrosclerosis, diabetic nephropathy, and reduced renal function without heavy proteinuria are also increasingly recognized. In some biopsy series, diabetic nephropathy and hypertensive nephrosclerosis each formed an important part of the renal burden, while microalbuminuria was more prevalent even among normotensive, nondiabetic patients.

These abnormalities may be related to metabolic disturbances associated with antiretroviral treatment, including insulin resistance, dyslipidemia, and altered body-fat distribution. Similar renal and metabolic findings have also been reported in HIV-infected cohorts in Sub-Saharan Africa who were not receiving antiretroviral treatment, raising the possibility that HIV infection itself can contribute to these cardiovascular and renal consequences.

Hepatitis C Virus Coinfection

Hepatitis C virus coinfection is common among people with AIDS, affecting approximately 30% of HIV-infected patients in the cited account. A large proportion of HIV-infected patients with glomerular disease are coinfected with hepatitis C virus, and hepatitis C virus is considered the likely cause of cryoglobulinemic membranoproliferative glomerulonephritis in those cases. Its contribution to other HIV-related glomerular diseases remains uncertain, so the distinction between the two infections is clinically consequential rather than merely terminological.

The characteristic hepatitis C virus–related renal lesion is cryoglobulinemic membranoproliferative glomerulonephritis. It may occur with the systemic manifestations of mixed cryoglobulinemia: purpura, arthralgias, Raynaud phenomena, and, in severe cases, skin necrosis or pulmonary hemorrhage. Laboratory findings can include hypocomplementemia, increased rheumatoid factor, and circulating type II cryoglobulins. The kidney lesion shows mesangial proliferation, double contours of glomerular capillaries, IgG, IgM, and C3 deposits, subendothelial electron-dense deposits, and cryoglobulin thrombi obstructing capillary lumens; vasculitis of extraglomerular vessels may also occur.

Clinical expression ranges from persistent non-nephrotic proteinuria and microscopic hematuria with preserved renal function to nephrotic syndrome, visible hematuria, and acute renal failure. Thus, the same coinfection can remain clinically quiet at one stage and become a rapidly destructive renal syndrome at another. The evidence also notes that hepatitis C virus–associated chronic liver disease may increase the hepatotoxicity of some antiretroviral agents, adding a treatment-related complication to the renal and hepatic disease burden.

Diagnosis and Clinical Assessment

Diagnosis of active chronic hepatitis C virus infection depends on more than antibody status. Anti-HCV antibodies detected by third-generation enzyme-linked immunosorbent assay indicate exposure, but the distinction between resolved and active infection requires detection of hepatitis C virus RNA in serum by a sensitive molecular assay, with a threshold of approximately 15 IU/ml. Chronic infection should therefore be established by the combination of anti-HCV positivity and hepatitis C virus RNA positivity.

Once active infection is identified, assessment must address both hepatic and extrahepatic injury. Liver disease may be staged by liver biopsy or by noninvasive biochemical and morphological methods, including FibroScan measurement of liver stiffness. These tests can avoid approximately half of liver biopsies and permit yearly fibrosis follow-up in untreated patients. The extrahepatic assessment is particularly important in AIDS because cryoglobulinemia-associated vasculitis and immune-complex renal disease may be clinically more consequential than the often mild or absent elevation of liver enzymes.

The diagnostic problem becomes still more complex after kidney transplantation. Hepatitis C virus–infected renal allograft recipients are prone to immune-complex-mediated glomerulonephritis, including de novo membranoproliferative glomerulonephritis associated with type II mixed cryoglobulinemia. These allografts often have very low cryocrit levels, usually below 5%, which can limit detection and characterization of cryoglobulins, while hepatitis C virus RNA may be much higher in the cryocrit than in serum. Renal biopsy may show chronic injury, mesangial proliferation, double contours, and parietal IgM and C3 deposits.

Electron microscopy may be necessary to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy. Membranoproliferative glomerulonephritis is associated with subendothelial electron-dense deposits, whereas transplant glomerulopathy shows radiolucent areas in the glomerular basement membrane. The two lesions can coexist, supporting a model in which humoral immunity and hepatitis C virus–related autoimmunity act together. Membranous glomerulonephritis has also been described in hepatitis C virus–infected renal allografts, although its connection with hepatitis C virus is less clear because cryoglobulins, immune complexes, and complement activation are usually absent.

Treatment, Toxicity, and Prognosis

The prognosis of glomerular disease in patients coinfected with HIV and hepatitis C virus is described as very poor for both patient survival and renal survival. Some studies suggest that antiretroviral therapy may alter this otherwise dismal course, but information about specific anti-hepatitis C virus treatment and immunosuppressive therapy remains limited. The viral load of hepatitis C virus may help explain conflicting observations about progression to an AIDS-defining illness or death: a clear correlation has been reported between higher hepatitis C virus viral load and the risk of AIDS progression and death, although not all studies reproduced the association.

Treatment decisions are constrained by toxicity. Interferon-based therapy can cause flu-like symptoms such as fever, fatigue, headache, myalgia, and arthralgia; blood disorders including anemia and neutropenia; and neuropsychiatric effects including depression and anxiety. These adverse effects lead to dose reduction in approximately 35–42% of patients and treatment discontinuation in about 30%. In patients with end-stage renal disease, the resulting decline in quality of life is not an incidental concern but part of the therapeutic balance.

Hepatitis C virus infection is often clinically muted in long-term dialysis. Asthenia, fatigue, and cognitive impairment are common in the dialysis population regardless of serologic status, while biochemical abnormalities may be overlooked amid hypertension, gastrointestinal bleeding, anemia, and vascular-access failure. Nevertheless, hepatitis C virus infection remains the most frequently recognized cause of liver damage in patients with chronic kidney disease receiving long-term dialysis, and it is associated with increased mortality in this population.

Quality of life provides another measure of the burden. In a study of 165 regular dialysis patients, 83 of whom were anti-HCV positive, hepatitis C virus positivity was independently associated with a lower mental component summary score on the SF-36 questionnaire, although no association with the physical component summary score was found. Depression may reflect the diagnosis itself, concern about long-term health, fatigue, or cognitive impairment; dialysis independently increases the prevalence of depression as well. The evidence therefore leaves open whether hepatitis C virus treatment could reduce mortality partly by improving quality of life, even when biological markers such as liver histology or virologic features do not immediately change.

Transplantation and Institutional Management

AIDS and hepatitis C virus coinfection also alter the pathway to kidney transplantation. All kidney transplant candidates require screening for hepatitis C virus, with enzyme immunoassay followed by nucleic acid testing in low-prevalence regions and nucleic acid testing as the initial test in high-prevalence settings, where a negative antibody test may not reliably exclude infection. Among candidates with active infection, as many as 25% may have advanced liver fibrosis on biopsy despite clinically compensated disease. Liver biopsy has therefore remained the gold standard in the cited guidance, and candidates with established or decompensated cirrhosis should be referred for consideration of combined liver-kidney transplantation.

Patients on the kidney waiting list require continuing surveillance, particularly where deceased-donor waiting times approach five to seven years. Candidates with positive nucleic acid tests may be placed on hold and referred to a hepatologist for evaluation and possible treatment. Those who have achieved a sustained virologic response should undergo nucleic acid testing at least annually to confirm its durability; relapse warrants hold status and consideration of retreatment. Patients who remain viremic require annual assessment to determine whether liver disease has progressed.

The timing of hepatitis C virus treatment is especially important because interferon after transplantation is associated with increased risk of renal allograft rejection. For this reason, efforts to eradicate hepatitis C virus are directed toward the pretransplant period whenever possible. A sustained virologic response before transplantation is reported to be durable in most patients after immunosuppression, and limited evidence suggests that pretransplant clearance might reduce the risks of posttransplant diabetes and immune-complex glomerular disease, although its effect on progression of liver injury remains uncertain.

In dialysis units, prevention depends on strict infection-control procedures rather than on the physical segregation of infected patients. A systematic review of 20 molecular virology studies could not conclusively establish a specific transmission route in any study, but every study implicated failures in infection-control procedures. In 18 of the 20 studies, some or all newly infected patients did not share a dialysis machine with the source patient, indicating that the internal dialysis-machine circuit plays, at most, a small role in nosocomial transmission. The KDIGO workgroup consequently did not recommend dedicated machines for hepatitis C virus–infected patients, and it also did not recommend isolating infected patients in a separate ward as an alternative to strict infection-control practice. AIDS thus appears within a broader institutional chain in which testing, treatment toxicity, waiting-list status, transplant eligibility, and infection prevention continually reshape the meaning of infection.